Akebia Therapeutics, Inc.
AKBAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Akebia Therapeutics, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Valued at $157.1M, AKBA is a micro-cap name in its sector. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Market Cap
$157.1M
Beta
0.18
P/E (TTM)
—
P/E (Fwd)
-1.57
EPS (TTM)
$-0.12
EPS (Fwd)
$-0.36
ROE
-109.4%
ROA
-1.1%
Cash
$155.5M
Total Debt
$199.2M
Free CF
$33.6M
52W Change
-81.3%
Annual Financials
Cash vs Debt
Where AKBA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AKBA finished 39.29% below its 150-day moving average ($1.12) and 42.37% below its 200-day moving average ($1.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AKBA overbought or oversold?
At the October 20, 2026 close, AKBA's RSI(14) was 23.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, AKBA has $155.5M in cash with $199.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $33.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -109.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $292.5M (2022) to $236.2M (2025), a 19% decline worth watching.
AKBA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing AKBA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.